Long-term disability outcomes in multiple sclerosis

Project Details

Prevention of irreversible disability is currently the most important goal of disease-modifying therapy for multiple sclerosis. Only limited information is available regarding the long-term impact of the available immunomodulatory therapies. Moreover, the information about the effectiveness of these therapies at various disease stages is lacking. Finally, there is currently no therapy approved for treatment of progressive multiple sclerosis phenotypes

This program studies accumulation of disability in different disease phenotypes and during different stages of multiple sclerosis. It focuses on the ability of disease modifying therapies to ameliorate accumulation of irreversible disability.

Researchers

  • A/Prof Tomas Kalincik, Project leader
  • Dr William Brown, Research fellow
  • Ms Jordana Hughes, MD student
  • Dr Anna He, Research associate
  • Mr Nathaniel Lizak, Research associate

Collaborators

  • The MSBase collaboration
  • Teams at University of Cambridge 
  • Cardiff University
  • University of Bristol
  • University College Dublin
  • Dresden University of Technology

Funding

  • NHMRC project grant 1083539, Treating progressive MS
  • NHMRC project grant 1129189, Precision treatment for multiple sclerosis
  • MSBase Fellowship
  • University of Melbourne

Research Outcomes

  1. Lizak N, Lugaresi A, Alroughani R, …Kalincik T, on behalf of the MSBase Study Group (2017) Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 88:196-203
  2. Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, et al. on behalf of the MSBase Study Group (in press) Long-term disability trajectories in primary progressive MS in patients - a latent class growth analysis. Mult Scler, accepted 18/03/2017
  3. Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E,… Kalincik T, on behalf of the MSBase Study Group (2016) Defining secondary progressive multiple sclerosis. Brain 139(9):2395
  4. Stewart T, Spelman T, Havrdova E… Kalincik T. (2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler 23(2):266-276
  5. Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287-98

Research Group

CORe Unit (Clinical Outcomes Research Unit)



Faculty Research Themes

Neuroscience

School Research Themes

Neuroscience & Psychiatry



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Medicine and Radiology

Unit / Centre

CORe Unit (Clinical Outcomes Research Unit)